Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C7H5O3.Ca |
| Molecular Weight | 314.304 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].OC1=C(C=CC=C1)C([O-])=O.OC2=C(C=CC=C2)C([O-])=O
InChI
InChIKey=VBIGULIJWJPALH-UHFFFAOYSA-L
InChI=1S/2C7H6O3.Ca/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2
| Molecular Formula | C7H5O3 |
| Molecular Weight | 137.1128 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Calcium salicylate is the calcium salt of salicylic acid. The anti-cancer effectiveness of calcium salicylate has been investigated on human HT-1080 fibrosarcoma cell lines. Low calcium salicylate concentrations did not retard tumor growth progression significantly but its cytotoxic characteristics were proven to be prominent by various morphological and immunocytological techniques - approximately 25% apoptosis after treatment with calcium salicylate. This compound up-regulated the expression of p53, p21 and Bax, and down-regulated Bcl-2 in HT-1080 cells. In addition, calcium salicylate is used in root canal filling material development.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: TP53 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16872361 |
|||
Target ID: CDKN1A (p21) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16872361 |
|||
Target ID: BCL2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16872361 |
|||
Target ID: Bax Sources: https://www.ncbi.nlm.nih.gov/pubmed/16872361 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
525 μg/L |
2 % 1 times / day steady-state, topical dose: 2 % route of administration: Topical experiment type: STEADY-STATE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
5282 μg/L |
81 mg 1 times / day steady-state, oral dose: 81 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
0.814 μg/mL |
30 % single, topical dose: 30 % route of administration: Topical experiment type: SINGLE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
56.4 μg/mL |
650 mg single, oral dose: 650 mg route of administration: Oral experiment type: SINGLE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4225 μg × h/L |
2 % 1 times / day steady-state, topical dose: 2 % route of administration: Topical experiment type: STEADY-STATE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
22010 μg × h/L |
81 mg 1 times / day steady-state, oral dose: 81 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
6.3944 μg × h/mL |
30 % single, topical dose: 30 % route of administration: Topical experiment type: SINGLE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
319.9 μg × h/mL |
650 mg single, oral dose: 650 mg route of administration: Oral experiment type: SINGLE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.62 h |
2 % 1 times / day steady-state, topical dose: 2 % route of administration: Topical experiment type: STEADY-STATE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.62 h |
81 mg 1 times / day steady-state, oral dose: 81 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
3.82 h |
30 % single, topical dose: 30 % route of administration: Topical experiment type: SINGLE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.23 h |
650 mg single, oral dose: 650 mg route of administration: Oral experiment type: SINGLE co-administered: |
SALICYLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9% |
SALICYLIC ACID serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:19 GMT 2025
by
admin
on
Mon Mar 31 17:48:19 GMT 2025
|
| Record UNII |
0841QCS0DK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000076614
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
PRIMARY | |||
|
C513091
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
PRIMARY | |||
|
DTXSID60890489
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
PRIMARY | |||
|
0841QCS0DK
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
PRIMARY | |||
|
C77337
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
PRIMARY | |||
|
SUB13199MIG
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
PRIMARY | |||
|
212-525-4
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
PRIMARY | |||
|
517068
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
PRIMARY | |||
|
824-35-1
Created by
admin on Mon Mar 31 17:48:19 GMT 2025 , Edited by admin on Mon Mar 31 17:48:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |